2016年12月
The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma
LEUKEMIA & LYMPHOMA
- 巻
- 57
- 号
- 12
- 開始ページ
- 2763
- 終了ページ
- 2770
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1080/10428194.2016.1195498
- 出版者・発行元
- TAYLOR & FRANCIS LTD
We previously developed a prognostic index, SIL, which includes advanced stage (5), soluble interleukin-2 receptor level (I), and elevated lactate dehydrogenase level (L) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP). This time we evaluated the index in a larger cohort and its utility in the risk stratification. The above three factors were independent risk of progression-free survival (PFS). Five-year PFS rates in the standard-risk (SIL index: 0 or 1, n = 367) and high-risk groups (SIL index: 2 or 3, n = 205) were 79% and 53%, respectively (p < 0.0001). When the patients were divided by age (<= 60 years and >60 years), the SIL index was a good prognostic indicator for PFS in both groups as well as divided by the number of extranodal involvement site (0-1 and >1). The SIL index is a simple and objective prognostic indicator in DLBCL.
- リンク情報
- ID情報
-
- DOI : 10.1080/10428194.2016.1195498
- ISSN : 1042-8194
- eISSN : 1029-2403
- PubMed ID : 27320054
- Web of Science ID : WOS:000385471000005